Literature DB >> 24463500

[Ciclosporin or infliximab for severe steroid refractory ulcerative colitis: GETAID study (Group d'Etudes Thérapeutiques des Affections Inflammatoires Digestives)].

M Zeitz1, S Nitschmann.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24463500     DOI: 10.1007/s00108-013-3434-1

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


× No keyword cloud information.
  4 in total

1.  [Updated German guideline on diagnosis and treatment of ulcerative colitis, 2011].

Authors:  A Dignass; J C Preiss; D E Aust; F Autschbach; A Ballauff; G Barretton; B Bokemeyer; S Fichtner-Feigl; S Hagel; K R Herrlinger; G Jantschek; A Kroesen; W Kruis; T Kucharzik; J Langhorst; M Reinshagen; G Rogler; D Schleiermacher; C Schmidt; S Schreiber; H Schulze; E Stange; M Zeitz; J C Hoffmann; A Stallmach
Journal:  Z Gastroenterol       Date:  2011-08-24       Impact factor: 2.000

2.  Infliximab versus ciclosporin in severe ulcerative colitis.

Authors:  Barrett G Levesque; William J Sandborn
Journal:  Lancet       Date:  2012-10-10       Impact factor: 79.321

Review 3.  Infliximab versus cyclosporine as rescue therapy in acute severe steroid-refractory ulcerative colitis: a systematic review and meta-analysis.

Authors:  Kah Hoong Chang; John P Burke; J Calvin Coffey
Journal:  Int J Colorectal Dis       Date:  2012-11-01       Impact factor: 2.571

4.  Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management.

Authors:  Axel Dignass; James O Lindsay; Andreas Sturm; Alastair Windsor; Jean-Frederic Colombel; Mathieu Allez; Gert D'Haens; André D'Hoore; Gerassimos Mantzaris; Gottfried Novacek; Tom Oresland; Walter Reinisch; Miquel Sans; Eduard Stange; Severine Vermeire; Simon Travis; Gert Van Assche
Journal:  J Crohns Colitis       Date:  2012-10-03       Impact factor: 10.020

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.